$VBIV SO would it be so crazy to predict that GSK may do a BO after this phase 3 data in order to get the rest of what VBIV has been working on for cheaper? Because if the other two studies and the vaccine platform VBIV is developing show even remotely comparable results then this company of 12 people would be worth like 1000% more later on? that would make sense to me because VBIV has just proven they can get TOP LINE results while doing multiple intense studies.
  • 8